Artificial intelligence (AI) is revolutionizing many industries, and healthcare and pharmaceuticals are no exceptions. In recent years, there has been a surge of interest in generative AI, which can generate new data based on existing data, and its potential applications in these fields. With its immense and tempting potential, generative AI can produce a wide range of outputs. However, it is essential to be cautious. The significant opportunity in AI requires careful analysis before the implications. This evaluation is particularly important in pharma, which is known for slow change, and is a highly regulated industry. The potential risks of inappropriately implementing new technology can be substantial. For example, consider the excitement surrounding IBM’s Watson Health a few years ago, which was expected to be able to detect complex cancers. Unfortunately, it failed to meet expectations.
Role of Generative AI in Healthcare
Drug Discovery
One potential application of generative AI in healthcare is drug discovery. According to Forbes, generative AI can assist in the drug discovery process by predicting how a drug will interact with a specific protein or target. By using machine learning algorithms, generative AI analyses large amounts of data and generates novel molecules that can be used as potential drugs faster than traditional methods. This can help to reduce the time and cost associated with drug discovery, and ultimately lead to the development of more effective treatments for a range of diseases.
Medical Imaging
Generative AI has the potential to significantly improve medical imaging by creating synthetic images that are similar to real images, but with lower noise and faster scan times. For example, researchers can use generative AI to create synthetic MRI images, which can help doctors make more accurate diagnoses and provide better treatment plans.
In traditional MRI scans, there is often a significant amount of noise in the images, which can make it difficult to identify subtle differences or abnormalities. By using generative AI to create synthetic MRI images, researchers can reduce this noise and provide clearer and more accurate images. Additionally, generative AI can be used to speed up MRI scan times, which can be particularly important for patients who are unable to stay still for extended periods of time.
Personalized Medicine
AI is being applied in healthcare to personalize medicine. By analyzing a patient’s genomic data, AI can identify genetic variations that may cause diseases and suggest personalized treatments based on the patient’s individual genetic makeup. This approach to medicine is called precision medicine, and it has the potential to revolutionize healthcare by allowing for more personalized and targeted treatments for individual patients.
For example, AI could be used to analyze a patient’s genetic data to identify the specific genetic mutations that are causing particular cancer. This analysis could then be used to suggest personalized treatment options, such as drugs that are designed to target specific genetic mutations.
AI in Pharma
Drug Design & optimization
In the pharmaceutical industry, AI helps with drug design and optimization. AI analyzes chemical structures and generates new compounds with specific properties, such as increased potency or reduced toxicity. This can accelerate the drug discovery process and potentially lead to the development of more effective and safer drugs.
Clinical Trial Design
AI also helps with clinical trial design. By generating synthetic patient data, AI simulates clinical trials and provides insights into potential outcomes. This can help pharmaceutical companies make more informed decisions about which drugs to bring to market and how to design clinical trials that are more efficient and effective.
Drug Repurposing
By analyzing existing drugs and their targets, generative AI suggests new therapeutic uses for these drugs. This can help pharmaceutical companies save time and money on the drug development process and potentially lead to the development of new treatments for previously untreatable diseases.
Insilico Medicine, a company specializing in AI-driven drug discovery, has received FDA orphan drug designation for a drug candidate designed to treat idiopathic pulmonary fibrosis (IPF). The drug was discovered and designed using AI-powered generative chemistry. AI algorithms were used to simulate the structure of small molecules that could potentially interact with the target proteins associated with IPF. This allowed for the identification of a new compound that could potentially treat the disease.
AI and Market Access
Market access remains one of the most complex links in the pharmaceutical value chain, and studies show it has grown in complexity significantly in recent years. The advent and widespread adoption of new digital technologies is changing expectations from patients, practitioners, and payers, while fluctuating and novel market pressures make it difficult to devise useful strategies.
Artificial intelligence (AI) is the most appropriate tool for cutting through this complexity and making data-driven market access decisions in pricing, faster reimbursement, stakeholder engagement and more.
AI & Pharma Marketing
All types of AI have the potential to revolutionize the way pharmaceutical companies market their products. By analyzing large amounts of data on HCP behaviour, generative AI helps companies develop more targeted and effective marketing strategies. This could include identifying the most effective channels to reach the customers, tailoring messaging to specific complex segments and even down to a segment of one, and predicting which types of marketing campaigns are most likely to drive engagement and sales.
One of the significant benefits of AI in pharma is its ability to identify rare disease patients and make precise predictions about whether a doctor is likely to switch their prescribing focus. AI can also be used to make personalised recommendations to doctors and patients, based on real-time data analysis. For instance, the company Novo Nordisk has incorporated AI in its pens, which track, monitor, and provide predictions and advice on a patient’s health, giving doctors and patients a complete picture of the patient’s health.
Generative AI has also emerged as a powerful tool for pharmaceutical marketers, enabling the rapid development of content such as articles, social media posts, graphics, and video tutorials. However, it has limitations in accounting for the complexities of human behavior and healthcare decision-making, and human oversight is critical to avoid targeting vulnerable populations, perpetuating biases, or violating ethical principles. Although generative AI can result in cost savings, faster production, and improved idea generation, it relies on potentially biased or inaccurate data sets and may generate nonsensical information so care must be taken with the data being used to train it. Therefore, it must be used cautiously, transparently, and with consideration of potential drawbacks. With appropriate oversight and safety measures, generative AI can be a valuable tool for pharmaceutical marketers.
Additional benefits
AI’s ability to analyse data also enables early diagnosis of diseases such as diabetes and cancer, which can help prevent the development of full-blown conditions. While great for patients, this requires the pharmaceutical industry to adapt to the changes in the market, such as non-drug competition from digital therapeutics and nanobots as well.
Risks
While AI offers many benefits, the issue of privacy and intrusion into patients’ lives remains a concern. The use of AI in the pharmaceutical industry needs to strike a delicate balance between providing value to patients and doctors while also protecting their privacy.
Benefits of AI in pharma industry
The benefits Pharma Industry can yield by using generative AI are not limited to only those mentioned above, but it affects the whole process, from manufacturing to marketing.
1. Streamlined Manufacturing:
Pfizer has implemented AI and machine learning in their manufacturing facilities to optimize production and reduce costs. They use real-time data analysis to monitor manufacturing processes and identify opportunities for improvement, such as reducing waste, increasing efficiency, and improving quality control. Another example is Merck, which has developed a digital twin of its manufacturing process using AI and machine learning. The digital twin simulates the production process and identifies areas for improvement, such as reducing batch-to-batch variability and improving product quality. AI can optimize production processes by identifying the most efficient and cost-effective manufacturing methods, reducing waste and increasing yield.
2. Improved Patient Outcomes:
AI can analyze patient data to identify patterns and correlations, enabling physicians to make more accurate diagnoses and develop more effective treatment plans.
3. Enhanced Regulatory Compliance:
AI can ensure compliance with regulatory requirements by analyzing data and identifying potential issues before they become problematic, reducing the risk of regulatory non-compliance.
4. Improved Supply Chain Management:
Supply chain management can be optimized by predicting demand, identifying bottlenecks, and optimizing inventory levels, ensuring that drugs are available when and where they are needed.
● AI can analyze data on historical sales, weather patterns, population demographics, and other factors to predict future demand for drugs. This allows pharmaceutical companies to plan their production and distribution more accurately and avoid overstocking or understocking.
● AI is also used in monitoring supply chain operations in real time, identifying potential bottlenecks and supply chain disruptions. This allows pharmaceutical companies to proactively address these issues, preventing delays in drug delivery and ensuring that drugs are available when and where they are needed.
● AI analyzes data on sales patterns, expiration dates, and other factors to optimize inventory levels. This helps to reduce waste by preventing drugs from expiring on the shelf while ensuring that there is always enough inventory to meet demand.
● AI provides end-to-end visibility across the supply chain, from raw materials to finished products. This helps to identify any gaps or inefficiencies in the supply chain and enables pharmaceutical companies to take corrective action before problems arise.
5. Immediate and personalized sales and marketing:
AI can personalize the customer experience and provide enhanced customer experience and strengthen the pharma – HCP engagement significantly.
Conclusion
There is a huge need to be putting AI at the heart of everything because it’s going to give us a much better picture of what’s going on – not just in pharma but also in the healthcare sector.
AI is also changing the business model in pharma, with some companies adopting an ecosystem approach to serving all diabetes patients, regardless of the drug they are using.
AI has become an essential tool in the pharmaceutical industry due to the availability of massive amounts of data and the need for non-linear, complicated models to untangle relationships in data. AI has revolutionized various aspects of drug discovery, clinical trials, medical affairs, regulatory, market access, sales and marketing, and patient care, and the pharmaceutical industry must have AI as a core tool underlying most processes to adapt to thrive in the future.
Found this article interesting?
At Eularis, we are here to ensure that AI and FutureTech underpins your pharma success in the way you anticipate it can, helping you achieve AI and FutureTech maturation and embedding it within your organisational DNA.
We are the leaders in creating future-proof strategic AI blueprints for pharma and can guide you on your journey to creating real impact and success with AI and FutureTech in your discovery, R&D and throughout the biopharma value chain and help identify the optimal strategic approach that moves the needle. Our process ensures that you avoid bias as much as possible, and get through all the IT security, and legal and regulatory hurdles for implementing strategic AI in pharma that creates organizational impact. We also identify optimal vendors and are vendor-agnostic and platform-agnostic with a focus on ensuring you get the best solution to solve your specific strategic challenges. If you have a challenge and you believe there may be a way to solve it with AR but are not sure how, contact us for a strategic assessment.
See more about what we do in this area here.
For more information, contact Dr Andree Bates abates@eularis.com.